Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosaprepitant dimeglumine
Drug ID BADD_D00963
Description Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Marketing Status Prescription; Discontinued
ATC Code A04AD12
DrugBank ID DB06717
KEGG ID D06597
MeSH ID C579707
PubChem ID 136086851
TTD Drug ID Not Available
NDC Product Code 0143-9384; 31722-165; 0006-3061; 67184-0540; 70447-0001; 63552-011; 55150-299; 16714-248; 68001-523; 70625-300; 71731-5111; 76339-141; 66039-904; 61662-0007; 0338-0008; 70860-783; 70860-782; 65085-0060; 14501-0064; 0143-9428; 65977-0080; 0781-3484; 52133-0045; 59651-111
Synonyms fosaprepitant | Emend for injection | fosaprepitant dimeglumine | L 785,298 | L785,298 | L-785,298
Chemical Information
Molecular Formula C30H39F7N5O11P
CAS Registry Number 265121-04-8
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C( C=C4)F.CNCC(C(C(C(CO)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Type I hypersensitivity10.01.03.006--Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Visual acuity reduced17.17.01.011; 06.02.03.001--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Wound dehiscence12.02.05.003--
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Subileus07.13.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Epigastric discomfort07.01.02.004--Not Available
Infusion site induration12.07.05.010; 08.02.05.009--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site pruritus23.03.12.006; 12.07.05.005; 08.02.05.004--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Staphylococcal infection11.02.05.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages